替格瑞洛用于急性冠状动脉综合征多支病变行经皮冠状动脉介入术患者抗血小板治疗中的短期有效性及安全性观察

被引：22

作者：

夏经钢 ^{[1
]}

曲杨 ^{[2
]}

胡少东 ^{[1
]}

许骥 ^{[1
]}

尹春琳 ^{[1
]}

徐东 ^{[1
]}

机构：

[1] 首都医科大学宣武医院心脏科

[2] 首都医科大学附属北京胸科医院病理科

来源：

中国医药 | 2015年 / 10卷 / 03期

关键词：

急性冠状动脉综合征; 替格瑞洛; 多支病变; 经皮冠状动脉介入治疗;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

摘要：

目的评价替格瑞洛用于急性冠状动脉综合征多支病变行经皮冠状动脉介入术抗血小板治疗的短期有效性及安全性。方法选择2013年5—8月首都医科大学宣武医院收治的120例急性冠状动脉综合征多支病变患者为研究对象,采用随机数字表法分为替格瑞洛组(60例,术前顿服180 mg,术后90 mg,2次/d)和氯吡格雷组(60例,术前顿服600 mg,术后75 mg,1次/d),比较2组患者的基线资料、冠状动脉病变特征、用药前和用药后5 d血小板计数和血小板抑制率、术后3个月内主要不良心血管事件,以及不良反应包括出血并发症的发生率。结果 2组患者基线资料、冠状动脉病变特征,用药前及用药后5 d血小板计数差异均无统计学意义(P>0.05)。替格瑞洛组术后5 d二磷酸腺苷诱导的血小板抑制率明显高于氯吡格雷组[(81±10)%比(76±12)%,P<0.05]。2组患者随访3个月,氯吡格雷组8例(13.3%)发生主要不良心血管事件,替格瑞洛组5例(8.3%)发生不良心血管事件,替格瑞洛组与氯吡格雷组相比主要不良心血管事件发生率差异无统计学意义(P>0.05)。2组不良反应差异无统计学意义(P>0.05)。结论替格瑞洛用于急性冠状动脉综合征多支病变行经皮冠状动脉介入术患者的抗血小板治疗具有良好的短期有效性和安全性。

引用

页码：289 / 293

页数：5

共 14 条

[1] 药物洗脱支架术后急性亚急性血栓发生的原因及救治分析 [J].

李志立 ;

曹义战 ;

艾永飞 ;

马文帅 ;

薛玉生 ;

杨欣国 ;

汤雁玲 ;

金葵花 .

中国急救医学, 2014, 34 (04) :327-330

[2] 经皮冠状动脉介入治疗术后急性、亚急性支架内血栓形成的危险因素分析 [J].

张燕 ;

任艺虹 ;

周超飞 ;

张庆考 ;

刘国树 ;

刘陪沛 .

中国循环杂志, 2013, 28 (01) :17-20

[3] 药物洗脱支架术后再内皮化延迟与晚期血栓形成 [J].

张琳 ;

张瑞岩 .

国际心血管病杂志, 2009, 36 (02) :91-93+97

[4]

2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction.[J].Jeffrey L. Anderson;Cynthia D. Adams;Elliott M. Antman;Charles R. Bridges;Robert M. Califf;Donald E. Casey;William E. Chavey;Francis M. Fesmire;Judith S. Hochman;Thomas N. Levin;A. Michael Lincoff;Eric D. Peterson;Pierre Theroux;Nanette K. Wenger;R. Scott Wright.Journal of the American College of Cardiology.2013, 23

[5]

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.[J].Glenn N. Levine;Eric R. Bates;James C. Blankenship;Steven R. Bailey;John A. Bittl;Bojan Cercek;Charles E. Chambers;Stephen G. Ellis;Robert A. Guyton;Steven M. Hollenberg;Umesh N. Khot;Richard A. Lange;Laura Mauri;Roxana Mehran;Issam D. Moussa;

[6]

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention.[J].Glenn N. Levine;Eric R. Bates;James C. Blankenship;Steven R. Bailey;John A. Bittl;Bojan Cercek;Charles E. Chambers;Stephen G. Ellis;Robert A. Guyton;Steven M. Hollenberg;Umesh N. Khot;Richard A. Lange;Laura Mauri;Roxana Mehran;Issam D. Moussa;Debabrata Mukherjee;Brahmajee K. Nallamothu;Henry H. Ting.Journal of the American College of Cardiology.2011, 24

[7]

Culprit Vessel Only Versus Multivessel and Staged Percutaneous Coronary Intervention for Multivessel Disease in Patients Presenting With ST-Segment Elevation Myocardial Infarction.[J].Pieter J. Vlaar;Karim D. Mahmoud;David R. Holmes;Gert van Valkenhoef;Hans L. Hillege;Iwan C.C. van der Horst;Felix Zijlstra;Bart J.G.L. de Smet.Journal of the American College of Cardiology.2011, 7

[8]

Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.[J].Eugenia Nikolsky.Vascular Health and Risk Management.2010, defa

[9] 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J].

Kushner, Frederick G. ;

Smith, Sidney C. ;

King, Spencer B. ;

Anderson, Jeffrey L. ;

Antman, Elliott M. ;

Bailey, Steven R. ;

Bates, Eric R. ;

Blankenship, James C. ;

Casey, Donald E. ;

Green, Lee A. ;

Hochman, Judith S. ;

Jacobs, Alice K. ;

Krumholz, Harlan M. ;

Morrison, Douglass A. ;

Ornato, Joseph P. ;

Pearle, David L. ;

Peterson, Eric D. ;

Sloan, Michael A. ;

Whitlow, Patrick L. ;

Williams, David O. .

CIRCULATION, 2009, 120 (22) :2271-2306

[10]

Incomplete Revascularization in the Era of Drug-Eluting Stents.[J].Edward L. Hannan;Chuntao Wu;Gary Walford;David R. Holmes;Robert H. Jones;Samin Sharma;Spencer B. King.JACC: Cardiovascular Interventions.2009, 1

← 1 2 →